BioRestorative Therapies
BioRestorative Therapies is a Melville, New York-based regenerative-medicine company developing cell and tissue therapies from adult stem cells, focused on disc/spine disease and metabolic disorders. Its lead candidate BRTX-100 is an autologous cultured mesenchymal stem-cell therapy for the non-surgical treatment of painful lumbosacral disc disorders, and ThermoStem targets obesity and metabolic disease using brown-adipose-derived stem cells; the company also runs a commercial biocosmeceutical platform and an investigational curved-needle delivery device. Formerly Stem Cell Assurance, the company renamed in August 2011 and in September 2026 announced a 1-for-20 reverse stock split to regain Nasdaq bid-price compliance.
Company Info
Upcoming Milestones & Key Dates
1-for-20 reverse stock split effective on Nasdaq Capital Market
Clinical Development Pipeline
BRTX-100
Target: Autologous cultured mesenchymal stem cells (bone-marrow derived)ThermoStem
Target: Brown-adipose-derived stem cells generating brown adipose tissueRecent News
No recent news updates available for this company.
Leadership Team
Katharyn Field
President, Chief Executive Officer and Interim Chief Financial Officer
Francisco J. Silva
Vice President of R&D and Chief Scientist
Careers & Job Openings
No active job listings. Check back later.